The fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER) trial

https://doi.org/10.1053/scds.2003.00009Get rights and content

Abstract

New evidence has shown that the highest risk of stroke is in the 48 to 72 hours immediately after a transient ischemic attack. No evidence currently exists to guide the optimal management of these patients. The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) trial aims to enroll this group of patients. The trial has a 2×2 factorial design. All patients will be on aspirin. Patients will be randomized to clopidogrel or placebo, and to simvastatin or placebo to ensure that these are both safe and effective treatments. Patients will be followed for 90 days.

References (27)

  • CARPIE Steering Committee

    A randomised, blinded trial of clopidogrel versus aspirin, in patients at risk of ischemic events (CAPRIE)

    Lancet

    (1996)

  • Swedish ASA low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events

    Lancet

    (1991)

  • A comparison of two doses of aspirin (30 mg vs. 283 mg daily) in patients after a transient ischemic attack of minor ischemic stroke

    N Engl J Med

    (1991)

    • Cited by (0)

    View full text
    Copyright © 2003 Published by Elsevier Inc.